摘要
目的:探讨孟鲁司特钠与西替利嗪及布地奈德联合治疗咳嗽变异性哮喘(CVA)的效果。方法:选取2021年1月—2023年1月汉川市妇幼保健院收治的92例CVA患儿作为研究对象,基于随机数表法将患儿分为对照组和观察组,各46例。对照组采用布地奈德治疗,观察组在对照组基础上给予孟鲁司特钠与西替利嗪联合治疗。比较两组临床症状缓解时间及治疗前后免疫指标、炎症因子、miR-155和miR-138表达水平。结果:观察组咳嗽消失时间、高热消失时间、呼吸困难缓解时间均早于对照组,差异有统计学意义(P<0.05)。治疗前,两组辅助型T细胞1(Th1)、辅助型T细胞2(Th2)、Th1/Th2、血清干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)水平、miR-155和miR-138表达水平比较,差异无统计学意义(P>0.05);治疗后,两组上述指标较治疗前均有不同程度改善,且观察组Th1、Th1/Th2、IFN-γ水平高于对照组,Th2、IL-4、IL-10、mi R-155、miR-138水平低于对照组,差异有统计学意义(P<0.05)。结论:孟鲁司特钠与西替利嗪及布地奈德联合治疗能有效调节CVA患儿Th1/Th2平衡,减轻炎症水平,同时也可以调节外周血miR-155、miR-138表达,有利于症状改善与预后恢复。
Objective:To explore the effect of Montelukast Sodium combined with Cetirizine and Budesonide in the treatment of cough variant asthma(CVA)in children.Method:A total of 92 children with CVA who admitted to Hanchuan Maternal and Child Health Hospital from January 2021 to January 2023 were selected as the study objects,and they were divided into the control group and the observation group according to the random number table method,with 46 cases in each group.The control group was treated with Budesonide,while the observation group was treated with Montelukast Sodium and Cetirizine on the basis of the control group.The remission time of clinical symptoms and the expression levels of immune indexes,inflammatory factors,miR-155 and miR-138 before and after treatment were compared between two groups.Result:The disappearance time of cough,disappearance time of high fever,and relief time of dyspnea of the observation group were earlier than control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of helper T cell 1(Th1),helper T cell 2(Th2),Th1/Th2,serum interferon-γ(IFN-γ),interleukin-4(IL-4),interleukin-10(IL-10),and the expression levels of miR-155 and miR-138 between two groups(P>0.05);after treatment,the above indexes of two groups were improved to varying degrees compared with those before treatment,and the levels of Th1,Th1/Th2 and IFN-γin the observation group were higher than those in the control group,while the levels of Th2,IL-4,IL-10,miR-155 and miR-138 were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Montelukast Sodium combined with Cetirizine and Budesonide can effectively regulate Th1/Th2 balance of CVA,reduce inflammation levels,and also regulate the expression of miR-155 and miR-138 in peripheral blood,which is beneficial for symptom improvement and prognosis recovery.
作者
刘巧荣
陈瑶华
LIU Qiaorong;CHEN Yaohua(Hanchuan Maternal and Child Health Hospital,Hanchuan 431699,China;不详)
出处
《中外医学研究》
2024年第1期5-8,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
